Set Your Location to See Relevant Information

Setting your location helps us to show you nearby providers and locations based on your healthcare needs.

TAK-071-2002 – PD Falls study

Objective

Booth Gardner Parkinson’s Care Center is conducting a Phase 2, randomized, double-blind, placebo-controlled crossover study to evaluate the effect of an investigational drug, TAK-071, when compared to placebo on gait in participants with Parkinson’s Disease (PD) who also have cognitive impairment.

Who may be eligible to participate?
  • Between 40 to 75 years of age
  • Have been diagnosed with PD
  • Has elevated risk for falls as indicated by at least 2 falls in the last 6 months before the screening visit
  • Has a caregiver who spends a minimum of 2 hours a day with the subject

Other inclusion/exclusion criteria apply.

What does participation involve?

The total amount of time a subject may be involved in the study is up to 23 weeks, including one 6-week (or less) period to test eligibility, two 6-week periods of receiving TAK-071 (or placebo), a 3-week period in between during which a subject receives neither, and up to 2 weeks for a follow-up period.

There will be a total of 5 clinic visits, with the screening visit lasting approximately 2 hours and each other visit lasting approximately 4-5 hours. There will be 3 phone visits, and each call is expected to take less than 1 hour.

Investigator

Pinky Agarwal, MD, FAAN

Clinical Trial Categories

  • Parkinson's Disease
Contact
EvergreenHealth Research Services at 425-899-5385
or EvergreenResearch@evergreenhealth.com

Contact Us

Call us at (425) 899-5385 or use our online information request form.

Online Form